Targeting PD-L1-CMTM6 interactions in myeloid cells triggers PD-L1 degradation and enhances cytotoxic T-cell expansion
This work highlights the importance of targeting PD-L1 recycling and intrinsic signaling, specifically in myeloid cells, to boost antitumor responses. Our studies suggest that H1A can provide a solution to the lack of responses seen with current therapeutics, while also revealing previously unknown intrinsic functions of PD-L1 in myeloid cells.
Authors
- Susan M. Harrington (ORCID: https://orcid.org/0000-0001-8112-0896)
- Emilia R. Dellacecca (ORCID: https://orcid.org/0000-0001-9031-2240)
- Whitney Barham (ORCID: https://orcid.org/0000-0002-1130-1971)
- Haidong Dong (ORCID: https://orcid.org/0000-0002-5782-2983)
- Jessica Naomi Lancaster (ORCID: https://orcid.org/0000-0003-0398-9988)
- Dallin S. Ashton (ORCID: https://orcid.org/0000-0002-2322-4862)
- Crystal Yan Lin (ORCID: https://orcid.org/0000-0001-7081-9888)
- Kevin D. Pavelko (ORCID: https://orcid.org/0000-0001-7555-1315)
- N Sun (ORCID: https://orcid.org/0000-0002-0735-7956)
- Zhiming Mao (ORCID: https://orcid.org/0000-0002-7705-9575)
- Michelle A. Hsu (ORCID: https://orcid.org/0000-0002-3214-2607)
- Fabrice Lucien (ORCID: https://orcid.org/0000-0001-6149-345X)
- Xin Liu (ORCID: https://orcid.org/0000-0002-6634-4012)
- Wenjing Zhang (ORCID: https://orcid.org/0000-0002-6694-6072)
- Jacob B. Hirdler
Institutions
- Mayo Clinic (US)
- Vanderbilt University (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1136/jitc-2025-012164
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00